EZH2 and diffuse large B-cell lymphoma: A subsequent phase 2 study confirmed the activity of tazemetostat in relapsed/refractory GC DLBCL, disclosing a higher response rate (29% vs. 15%) in patients with activating EZH2 mutations [26].